Cobra Biologics Wins Manufacturing Agreement

Cobra Biologics, the international clinical and commercial manufacturer of biologics and pharmaceuticals, today announces that it has signed an agreement with a clinical stage biotechnology company to produce a Drug Substance under cGMP. 

The product, consisting of live bacteria, will be used for toxicology and clinical studies for treatment of a metabolic disorder. The disorder is a rare genetic disease leading to kidney failure and end stage renal disease.

The newly aquired Cobra facility in Matfors, Sweden, has a long standing experience in large scale microbial production and will perform both the upstream and downstream work to isolate and purify the live bacteria.

Peter Coleman, CEO of Cobra Biologics said: "We are very pleased to have been selected by this company as this underlines Cobra's extensive experience and expertise in producing microbial based products for clinical trials through to commercial supply."

For more information about Cobra Biologics, please contact Peter Coleman, CEO, on +44 (0)1782 714181 or email peter.coleman@cobrabio.com

For media enquiries, please contact Tristan Jervis or Alex Heeley on +44 (0)207 861 3019 or email: t.jervis@defacto.com.  

About Cobra Biologics

Cobra Biologics is a leading international clinical and commercial manufacturer of biologics and pharmaceuticals with three GMP approved facilities. We offer a broad range of integrated and stand-alone development services, stretching from cell line development through to the commercial supply of investigational medicinal product. We take pride in manufacturing excellence and being a trusted provider, delivering what we promise and helping our customers to develop drugs for the benefit of patients. Cobra Biologics provides manufacturing solutions to the biologics and pharmaceutical industry covering antibodies, recombinant proteins, viruses, DNA, cellular therapeutics and small molecules.